Review of 2015 San Antonio Breast Cancer Symposium:ductal carcinoma in situ

doi:10.3877/cma.j.issn.1674-0807.2016.04.002

Abstract

Abstract:

In the San Antonio Breast Cancer Symposium in 2015, the diagnosis and treatment of early breast lesions and ductal carcinoma in situ (DCIS) remained one of hot topics. In this article, we reviewed the report on DCIS presented by Professor Li Yi from Baylor College of Medicine, USA, in this symposium, mainly focused on molecular network mechanism of DCIS and its progression to invasive cancer.

Key words: Breast neoplasms, Atypical hyperplasia, Carcinoma in situ

Li Fu, Yaqing Li, Aiping Shi. Review of 2015 San Antonio Breast Cancer Symposium:ductal carcinoma in situ[J]. Chinese Journal of Breast Disease(Electronic Edition), 2016, 10(04): 200-203.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2016.04.002

https://zhrxbzz.cma-cmc.com.cn/EN/Y2016/V10/I04/200

References 32

[1]	Hartmann LC, Degnim AC, Santen RJ, et al. Atypical hyperplasia of the breast-risk assessment and management options[J]. N Engl J Med,2015,372(1):78-89.
[2]	Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease[J]. Endocr Relat Cancer,2001,8(1):47-61.
[3]	Santen RJ, Mansel R. Benign breast disorders[J]. N Engl J Med,2005,353(3):275-285.
[4]	Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression[J]. J Pathol,2011,223(2):307-317.
[5]	Degnim AC, Visscher DW, Berman HK, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study[J]. J Clin Oncol,2007,25(19):2671-2677.
[6]	Stommel JM, Wahl GM. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation [J]. EMBO J,2004,23(7):1547-1556.
[7]	Ito A, Kawaguchi Y, Lai CH, et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation [J]. EMBO J,2002,21(22):6236-6245.
[8]	李小曼, 徐红德, 蔺美娜, 等. DNA 损伤修复反应的双刃剑效应在肿瘤与衰老发生发展中的作用[J]. 中国细胞生物学学报,2013,35(2):134-140.
[9]	Lakhani SR, Ellis LO, Schnitt SJ, et al. WHO classification of tumours of the breast[M]. Lyon: IARC Press,2012:88.
[10]	Sinha VC, Qin L, Li Y. A p53/ARF-dependent anticancer barrier activates senescence and blocks tumorigenesis without impacting apoptosis[J]. Mol Cancer Res,2015,13(2):231-238.
[11]	李玉梅, 吴穷, 秦叔逵. MDM2 在恶性肿瘤中的研究进展[J]. 临床肿瘤学杂志,2012,17(3):277-280.
[12]	Wan L, Lu X, Yuan S, et al. MTDH-SND1 interaction is crucial for expansion and activity of tumor-initiating cells in diverse oncogene- and carcinogen-induced mammary tumors[J]. Cancer Cell,2014, 26(1):92-105.
[13]	Shi A, Dong J, Hilsenbeck S, et al. The status of STAT3 and STAT5 in human breast atypical ductal hyperplasia [J]. PLoS One,2015,10(7):e0132214.
[14]	Haricharan S, Dong J, Hein S, et al. Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy[J].Elife,2013,2: e00996.
[15]	Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges[J]. J Natl Cancer Inst,2004,96(12):906-920.
[16]	Partridge AH, Elmore JG, Saslow D, et al. Challenges in ductal carcinoma in situ risk communication and decision-making: report from an American Cancer Society and National Cancer Institute workshop[J]. CA Cancer J Clin,2012,62(3):203-210.
[17]	Collins LC, Tamimi RM, Baer HJ, et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study[J]. Cancer,2005,103(9):1778-1784.
[18]	Lee RJ, Vallow LA, McLaughlin SA, et al. Dutal carcinoma in situ of the breast[J]. Int J Surg Oncol,2012,2012:123549.
[19]	Abba MC, Gong T, Lu Y, et al. A molecular portrait of high-grade ductal carcinoma in situ[J]. Cancer Res,2015,75(18):3980-3990.
[20]	Mardekian SK, Bombonati A, Palazzo JP. Ductal carcinoma in situ of the breast: the importance of morphologic and molecular interactions[J]. Hum Pathol,2016,49:114-123.
[21]	Volinia S. Unexpected findings of variability in microRNAs suggest roles in human genetics[J]. Genome Med,2012,4(8):69.
[22]	Beretov J, Wasinger VC, Millar EK, et al. Proteomic analysis of urine to identify breast cancer biomarker candidates using a label-free LCMS/MS approach [J]. PLoS One,2015,10(11): e0141876.
[23]	Gauthier ML, Berman HK, Miller C, et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors[J]. Cancer Cell, 2007, 12(5):479-491.
[24]	Gauthier ML, Pickering CR, Miller CJ, et al. p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue[J]. Cancer Res,2005,65(5):1792-1799.
[25]	Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis[J]. J Natl Cancer Inst,2010,102(9):627-637.
[26]	Timoshenko AV, Chakraborty C, Wagner GF, et al. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer[J]. Br J Cancer,2006,94(8):1154-1163.
[27]	Knudsen ES, Pajak TF, Qeenan M, et al. Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression[J]. J Natl Cancer Inst,2012,104(23):1825-1836.
[28]	Elsarraj HS,Hong Y,Valdez KE,et al. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion[J]. Breast Cancer Res,2015,17:128.
[29]	Scribner KC, Behbod F, Porter WW. Regulation of DCIS to invasive breast cancer progression by Singleminded-2s (SIM2s)[J]. Oncogene,2013,32(21):2631-2639.
[30]	Rizki A, Bissell MJ. Homeostasis in the breast: it takes a village[J].Cancer Cell,2004,6(1):1-2.
[31]	Allinen M, Beroukhim R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer[J]. Cancer Cell, 2004,6(1):17-32.
[32]	Hu M, Yao J, Carroll DK, et al. Regulation of in situ to invasive breast carcinoma transition[J]. Cancer Cell,2008,13(5):394-406.

Please choose a citation manager

Content to export